Currently, the lack of strong evidence indicating either specific mutations or selective activation of specific PI3K isoform(s) during cSCC carcinogenesis, in particular during progression to metastatic cSCC, makes it difficult to envisage which selective PI3K inhibitor(s) or which specific drugs combination(s) could be beneficial in this context. This evidence concerns the gene PIK3CA and skin squamous cell carcinoma.